Anokion

About:

Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.

Website: http://anokion.com/

Top Investors: Versant Ventures, Novartis Venture Fund, Novo Ventures, Celgene, Foundation for Innovation and Technology (FIT)

Description:

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.